Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis. Tang Y, Fan Y. BMC Cancer 2024;24:1155.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tang Y, Fan Y. Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis. BMC Cancer 2024;24:1155.
PMID: 39289671